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Abstract  
Background: TMS is effective in the treatment of major depressive disorder (MDD) in 
placebo-controlled trials and naturalistic out-patient studies. In Australia, TMS receives no 
rebate (currently), thus, privately insured patients generally receive this treatment as 
inpatients. Aim: A naturalistic study of the effects of TMS on depressive episodes of MDD in 
private hospital inpatients, to determine whether TMS is effective in severe depression, and 
whether age or gender impact on outcome. Method: Pre- and post-treatment HAMD6, visual 
analogue scale (VAS6) for depression, and CGI-S. In addition, a mid-treatment VAS6. 
Patients were grouped according to HAMD6 severity (mild, moderate, severe). Treatment: 
daily, 10 Hz, 4 second trains, a total of 75 trains at 110% resting motor threshold applied to 
the LDLFC. A course of treatment - 20 daily sessions over 26 days. Repeated measures 
ANCOVA were used to understand the impact of time, gender and age on depression levels.  
Results: 52 patients with MDD participated – 35% had previously received TMS. Overall, 
69% achieved remission – including 63.2% (12/19) of those with severe depression. Neither 
age nor gender impacted on outcome. Conclusion: A naturalistic inpatient study of TMS 
treatment of MDD produced remission in 69% of 52 patients – including 63.2% (12/19) with 
severe depression. As 35% of patients had received TMS previously, the results were better 
than might otherwise be expected. Neither age nor gender impacted on outcome. 
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Introduction  
Major depressive disorder (MDD) is common, painful and difficult to treat. One third of 
patients do not respond to the first antidepressant administered (1), and one third do not 
benefit from adequate trials of known antidepressant medication (2,3). 
  
Transcranial magnetic stimulation (TMS) is effective in treatment resistant MDD, as 
demonstrated in randomized placebo-controlled trials (4,5) and confirmed by meta-analyses 
(6,7). It is recommended as a treatment for MDD in the guidelines of many professional 
bodies (8,9). 
  
The clinician is concerned with the likelihood of improvement of individual patients. In 
randomized placebo-controlled trials of TMS in MDD, 1) Levkovitz et al (10) used an H-coil 
(which likely stimulates more extensively than the figure eight coil) and reported at 5 weeks, 
remission rates of 32.6% for actively treated, and 14.6% for sham treated patients, 2) George 
et al (5) reported at 3 weeks, remission rates of 14.1% for actively treated, and 5.1% for sham 
treated patients, and 3) O’Reardon et al (4) reported at 6 weeks, the remission of 17.4% for 
actively treated, and 8.2% of sham treated patients.  
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With the antidepressant effects of TMS demonstrated in academic studies, the question 
becomes, is it useful in the real world, where patients suffer comorbidities, use substances, 
experience suicidal thoughts and are already consuming psychiatric medication? Naturalistic 
outpatient studies include, 1) Carpenter et al (11), 307 patients (42 US TMS services), 
reported objective remission in 37.1%, and subjective remission in 28.7-26.5%, 2) Galletly et 
al (12), 65 patients (Adelaide, Australia) reported remission in 28%, and 3) Rostami et al 
(13), 248 patients (Tehran, Iran) reported response in 45% of patients.  
 
In Australia, there is currently no reimbursement for TMS treatment. Thus, in private 
practice, unless there is a benefactor (as in the Galletly et al (12) study), insured patients must 
deteriorate to the point of requiring hospitalization, so that the cost of treatment can be 
recovered from the hospitalization rebate. Saint Helen’s Private Hospital (Hobart, Australia) 
has been providing TMS treatment since 2004, and routinely collects clinical data using 
standardized instruments. 
Some reports indicate younger people have a better response (14), but, others find age has no 
influence (13, 15). The impact of gender on outcome remains unexplored (16). 
 
A few comparisons of ECT and TMS have indicated ECT has a stronger antidepressant effect 
(17). This has led to uncertainty about the efficacy of TMS in severe MDD.  
 
The aim of this study was to determine whether TMS is useful in the treatment of MDD 
suffered by private psychiatric hospital inpatients. We determined the effect of TMS on the 
total MDD population, and on sub-populations of mild, moderate and severe depression. We 
also examined whether age or gender impact on outcome.  
 
 
Method  
The protocol and conduct of the study, and the publication of this report was sanctioned by 
the institutional ethics committee.  
  
The study conducted through 2017. 
  
Subjects were inpatients at a private psychiatric hospital, all suffering MDD and receiving 
antidepressant medication. All to have failed to respond to at least two courses of different 
antidepressants at appropriate doses administered for appropriate periods (thus, qualifying as 
treatment resistant MDD, or TRD (3)). Exclusion criteria: a history of epilepsy or currently 
pregnant, metal objects in the head or pacemaker in the chest, currently abusing or 
withdrawing from substances.  
  
Treatment: Stimulation was provided by a MagPro device with a MagVenture Cool-B65 coil. 
Daily - 10 Hz, 4 second trains, 26 second inter-train interval, a total of 75 trains, at 110% 
resting motor threshold, applied 6 cm anterior to the site of the resting motor threshold on the 
left side. A course of treatment was 20 daily sessions over 26 days, with a 2-day rest period 
after each 5 treatments.  
  
Routinely applied metrics: before and on completion of treatment: 1) the six-item Hamilton 
Depression Rating Scale (HAMD6) (18), 2) a six-item visual analogue scale (VAS6) (19), 
and 3) the Clinical Global Impression of Severity (CGI-S) (20). In addition, mid-way through 
the course (after 10 treatments) a further VAS6 was administered. 
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The HAMD6 items examine, 1) depressed mood, 2) work and energy, 3) somatic symptoms, 
4) feelings of guilt, 5) anxiety (psychic), and 6) retardation.  
  
The subjective VAS6 was designed to complement the objective HAMD6. Accordingly, the 
anchor points at either end of 10 cm lines: No depression – Worst possible depression; 
Activities give normal pleasure – Activities give no pleasure; No physical health concerns – 
Extreme health concerns; No feelings of guilt – Extreme feelings of guilt; and Not anxious – 
Most anxious possible. The 6
th
 HAMD6 item concerns ‘retardation’ - in an inexact match we 
chose VAS6 anchor points: No concentration problems – Most possible concentrations 
possible.  
  
The term, ‘remission’, is applied when symptom levels are low or absent (21), and is 
operationalized as HAMD6 score of <4 (22-24). ‘Partial remission/relapse – residual 
symptoms’ has been described (1,21) as an intermediate state, which can be operationalized 
as HAMD6 scores of 5 and 6. ‘Relapse’ describes the return of a depressive episode, after a 
period of remission (21,23); operationalized as a HAMD6 score of >7 (22,25). 
  
Bech et al (22) equate a HAMD6 score of 7-8 with ‘mild ICD-10 depression’, 9-11 with  
‘moderate ICD-10 depression’ and 12 and above with ‘severe ICD-10 depression’. We 
compared the admission and discharge HAMD6 scores for the total sample, and for these 
three depression levels.  
  
Data Analyses  
Descriptive statistics were used to describe participants and the number of participants at the 
different depression severity levels before and after treatment. Repeated measures ANCOVA 
was used with time as the repeated measure, gender as the between subject factor, covaried 
for age to understand if there were significant changes in symptoms with time, between 
gender and whether age was associated with symptom change. We also explored whether 
prior treatment (ECT or TMS) was associated with symptom change.  
  
  
Results  
Participant Characteristics  
Over the year of the study, a total of 52 individuals completed a course of treatment, and 6 
experienced relapse and completed a second course – for a total of 58 courses of treatment. 
Only the first courses of treatment were used in the following analyses. Table 1 shows the 
demographic characteristics of the participants. On average, the participants had over 18 
years of psychiatric history, were taking over 2 types of psychotropic medications, 31% had 
previously received electroconvulsive treatment and 35% had previously received TMS 
treatment (but not in the preceding 6 months).  
 
Neighbourhood socioeconomic disadvantage was measured using the Socio-Economic  
Indexes for Areas (SEIFA) Disadvantage Index corresponding to the participant’s postcode 
of residence (Australian Bureau of Statistics, 2013). The SEIFA of participants was slightly 
below the Australian average (M=1000, SD=100), t(51)=- 
2.34, p=0.02.  
 
Table 1. Participant characteristics (N=52)  
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ECT, Electroconvulsive Therapy; SEIFA, socio-economic indexes for areas  
  
Pre/Post Outcomes  
Repeated measures ANCOVA with Time as the repeated measure and gender as the 
independent variable covaried for age showed a significant reduction in HAMD6 and CGI 
Total scores post treatment (see Table 2). There was no main effect of gender on HAMD6 or 
CGI scores, age was not a significant factor in the analyses, indicating neither age nor gender 
impacted on outcomes of depression from the acute TMS sessions. The analyses were re-run 
to explore any effects of prior ECT or TMS treatment. There were no significant main effects 
of these prior treatments on the HAMD6 or CGI over time. 
 
Table 2. Pre-post objective scores for series of 5 TMS sessions (N=52)  
 Pre Post F (time main  
effect) 
p Partial eta 
squared 
HAMD6 Total M 
(SD) 
10.89 (1.96) 4.50 (3.33) 25.2 <.001 0.34 
CGI Total M 
(SD) 
4.38 (0.80) 2.23 (1.18) 17.2 <.001 0.26 
 
 
For the VAS there were 4 participants who did not complete the third time point leaving 48 
participants (as they went into remission and were discharged before the 20
th
 treatment). The 
VAS fell from 40.0 to 26.8 (11 days later) followed by 20.2 (a further 11 days later) (see 
Figure 1). Repeated measures ANOVA showed a significant reduction in VAS score 
[F(2,44)=11.3; p<.001, Eta
2
=.20] but no significant gender difference (p=.97), or impact of 
age (p=.86).  
 
Outcomes by HAM6 Severity Ratings  
Table 3 shows 69% of patients (36/52) achieved remission. Of the 19 patients in severe 
depression before treatment, 63.2% (12) achieved remission. Similarly, of those with 
moderate depression, 75% (21/28) achieved remission, as did 75% (3/4) of those with mild 
depression.  
 N   M   SD   Range   
Age     43.8   15.5   20-76   
Sex   38 female (73%)   
14 male (27%)   
      
SEIFA     978.4   64.2   825-1089   
Prior ECT   16 (31%)         
Prior TMS   18 (35%)         
Average number of psychotropic 
medication types   
  2.4    0.7   2-5   
Currently taking 1 antidepressant   6 (11.5%)         
Currently taking >1 antidepressant   46 (88.5)         
Current anticonvulsant   7 (13.5)         
Currant antipsychotic   7 (13.5)         
Current lithium   7 (13.5)         
Current other psychotropic medication   52 (100%)         
Length psychiatric history (years)     18.2   12.2   1-40   
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Table 3. Number of participants in each HAMD6 range before and after treatment  
HAMD6 scores: <4 = remission; 5, 6 = residual symptoms – partial remission; 7, 8 = mild depression; 9-11 = 
moderate depression; >12 = severe depression (Bech et al, 2007).  
 
Discussion  
We chose the HAMD6 as it is preferred to the HAMD17 in terms of transferability, 
scalability and responsiveness (26,27,2); it is unidimensional (29,30,31) and is brief enough 
to be easily managed in a busy service clinic.  
  
Our results (69% of MDD patients achieving remission) are (as expected) superior to those of 
controlled trials (4,5). Our patients were taking a range of antidepressants while those in 
controlled trials are medication free - evidence indicates different treatments may act 
synergistically (32). Our study provided what treating staff believed to be state of the art 
treatment; this would have been conveyed to patients, thus the placebo effect would be 
heightened. Slight treatment parameter differences between our study and the cited controlled 
trials may possibly (unlikely) have influenced the outcome. As mentioned, in Australia at the 
moment, the cost of TMS is not covered by the government or private insurers, so that in 
private practice, patients must be admitted to hospital to allow this cost to be recovered from 
the hospitalization rebate. Thus, when these people received TMS treatment for MDD, they 
were inpatients, which would also have contributed to their recovery. Finally, 35% had 
received TMS previously, and if TMS produces a beneficial effect at first treatment, it will do 
so at subsequent treatments. Thus, this 35% of patients were very likely to achieve substantial 
benefit. 
 
Our results were also (as expected) superior to the 28% remission of the naturalistic 
outpatient study of Galletly et al (12). Due to commercial circumstances, we provided 
inpatient care – thus, for our patients, the stressors of everyday life were replaced by support 
and encouragement from trained clinical staff.  
 
This was the first study (to our knowledge) to examine the effect of TMS on various levels of 
depression. For moderate and mild depression, remission was achieved in 75% of cases. In 
severe depression, remission was achieved in 63.2% of cases. This is important new 
information - that TMS is indicated in not only in mild and moderate, but also in severe 
MDD. Again, that 35% of our patients had previous experience of TMS is a complication.  
 
Neither age nor gender impacted on outcome. The absence of an influence of age on outcome 
is consistent with Rostami et al (13). While the numbers in this study were small - 38 females 
Pretreatment Post-treatment     Totals  
 <4  
Remission  
5, 6  
Residual  
Symptoms 
7, 8  
Mild  
Depression 
9-11  
Moderate  
Depression 
>12  
Severe  
Depression 
  
<4  0  0  0  0  0  0 (0%)  
5, 6  0  0  0  1  0  1 (2%)  
7, 8  3  1  0  0  0  4 (8%)  
9-11  21  4  1  2  0  28 (54%)  
>12  12  1  2  1  3  19 (37%)  
 36 (69%)  6 (12%)  3 (6%)  4 (8%)  3 (6%) 52 (100%)  
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and 20 males – the absence of a significant difference indicates that any actual difference 
must be minor. There were also no differences in symptom reduction in participants who had 
or had not had past ECT or TMS treatment, suggesting outcomes from acute TMS are not 
influenced by these prior treatments.  
  
We used two objective metrics (HAMD6 and CGI) and the results were in agreement. We 
also used a subjective measure (VAS6). The results of the objective and subjective were also 
in agreement, which gives confidence in the findings. The graph of the VAS6 results [Figure 
1] indicates an orderly decline in subjective depression. This is as anticipated, but has not 
been previously demonstrated (to our knowledge). We believe the VAS6 considered in this 
manner can illustrate/demonstrate the placebo response. Occasionally, a patient is 
encountered who manifests dramatic early improvement, which is lost by the 20
th
 treatment - 
the VAS6 at three points in time can usefully quantify the good improvement midway 
through treatment which is lost by the end of treatment. 
 
 
Figure 1. VAS Scores at baseline, 11 days post baseline and 22 days post baseline.  
 
In current clinical practice, all patients who come to TMS have failed at least one or two trials 
of antidepressants, and satisfy the criteria for TRD. Thus, all of the patients in this study 
presented difficult clinical challenges, not simply those who, on this occasion, had a HDRS6 
score in the severe range. The overall remission rate of 69% (albeit assisted by hospital 
admission, and that 35% of patients were known TSM responders) indicates TMS is a highly 
effective therapy by current standards.  
  
TMS is effective in mild, moderate and severe depression. It should be available to inpatients 
and out patients in private and public settings. 
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